Alteogen Enters License Deal With Daiichi Sankyo For ALT-B4 In Subcutaneous ENHERTU Development
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
Fabricated remarks on Japan's nuclear wastewater release misrepresent Trump interview from 2023
After Donald Trump was re-elected US president, a screengrab of his 2023 interview with former Fox News host Tucker Carlson ...
FiercePharma3d
Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
A tiny grain of nuclear fuel is pulled from ruined Japanese nuclear plant, in a step toward cleanup
The nuclear fuel sample, the size of a grain of rice, was placed into a secure container Thursday, marking the end of the ...
Japan electric company removes small debris from Fukushima nuclear plant
Japanese nuclear plant workers for the first time have removed a small amount of melted fuel from one of the Fukushima ...
world-nuclear-news4d
Fuel debris sample extracted from Fukushima Daiichi reactor
Tokyo Electric Power Company announced it has successfully completed the trial removal of a sample of fuel debris from the ...
Breakthrough at Fukushima: First Nuclear Fuel Sample Extracted from Reactor
A robot tasked with searching the wreckage inside Fukushima Daiichi's Unit 2 reactor has retrieved a sample of melted nuclear fuel.
A robot retrieves the first melted fuel from Fukushima nuclear reactor
A remote-controlled robot has safely returned with a tiny piece of melted fuel it collected from inside one of three damaged ...
Indiatimes14d
Champion Dai-ichi Technologies India Limited News
Russia is pleased about the first meeting in five years between PM Narendra Modi and President Xi Jinping in Kazan during the BRICS Summit. Russian Ambassador Denis Alipov highlights the importance of ...
Investing14d
DSNKY Share News Today
TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca (NASDAQ:AZN)'s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous... SHIRLEY, N.Y., ...